An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients

Overview

The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV48108.

Full Title of Study: “A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108″

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: August 2015

Interventions

  • Drug: TV48108
    • TV48108 15, 60, 120 μg
  • Drug: Placebo
    • Placebo Comparator

Arms, Groups and Cohorts

  • Experimental: TV48108 – Healthy Volunteers
    • Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg
  • Placebo Comparator: Placebo – Healthy Volunteers
    • Placebo
  • Experimental: TV48108 15 µg COPD
    • Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.
  • Experimental: TV48108 60 µg COPD
    • Stage 2
  • Experimental: TV48108 120 µg COPD
    • Stage 2 .

Clinical Trial Outcome Measures

Primary Measures

  • Baseline adjusted forced expiratory volume in 1 second area under the curve over 12 hours (FEV1 AUC0-12h).
    • Time Frame: Day 1 (pre-dose, up to 12 hours post-dose)

Secondary Measures

  • Baseline Adjusted Trough 12 hour forced expiratory volume in 1 second (FEV1)
    • Time Frame: Day 1 (pre-dose, up to 12 hours post-dose)
  • Percentage of Participants with Adverse Events
    • Time Frame: 28 Days

Participating in This Clinical Trial

Inclusion Criteria

Stage 1 (Healthy Volunteers)

  • Male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg with a body mass index (BMI) of less than 30 kg/m^2.
  • In good health as determined by medical and psychiatric history, physical examination, electrocardiogram (ECG), serum chemistry, hematology, urinalysis, and serology.
  • Other criteria apply, please contact the investigator for more information

Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)

  • Male or female; 40 to 75 years of age, inclusive with a minimum body weight of 40 kg
  • Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack years at the screening visit
  • Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines.
  • Other criteria apply, please contact the investigator for more information

Exclusion Criteria

Stage 1 (Healthy Volunteers)

  • History or current evidence of a clinically significant or uncontrolled disease
  • Any disorder that may interfere with the absorption, distribution, metabolism or excretion of study drugs.
  • History of severe allergy to milk protein
  • Active smokers or former smokers who quit within 3 months of the first dose of study drug. Former smokers with greater than five-pack years (ie, the equivalent of one pack per day for five years) are also excluded.
  • Other criteria apply, please contact the investigator for more information

Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)

  • Recent history of hospitalization due to an exacerbation of airway disease within 3 months
  • Need for increased treatments of COPD within 6 weeks prior to the screening visit
  • History of and/or current diagnosis of asthma
  • Known α1 antitrypsin deficiency, active lung infections (such as tuberculosis or pneumonia), and lung cancer are absolute exclusionary conditions
  • Other criteria apply, please contact the investigator for more information

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Teva Branded Pharmaceutical Products R&D, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Teva Medical Expert, MD, Study Director, Teva Pharmaceuticals USA

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.